KR950704483A - 사이클린 복합체 재배열 및 그것과 관련된 용도(cyclin complex rearrangement and uses related thereto) - Google Patents

사이클린 복합체 재배열 및 그것과 관련된 용도(cyclin complex rearrangement and uses related thereto)

Info

Publication number
KR950704483A
KR950704483A KR1019950701512A KR19950701512A KR950704483A KR 950704483 A KR950704483 A KR 950704483A KR 1019950701512 A KR1019950701512 A KR 1019950701512A KR 19950701512 A KR19950701512 A KR 19950701512A KR 950704483 A KR950704483 A KR 950704483A
Authority
KR
South Korea
Prior art keywords
cyclin
complexed
kinase
seq
antibody
Prior art date
Application number
KR1019950701512A
Other languages
English (en)
Other versions
KR100331363B1 (ko
Inventor
에이치. 비치 데이빗
시옹 유에
Original Assignee
죤 마로니
콜드 스프링 하버 레보레이토리
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27130450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR950704483(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 죤 마로니, 콜드 스프링 하버 레보레이토리 filed Critical 죤 마로니
Publication of KR950704483A publication Critical patent/KR950704483A/ko
Application granted granted Critical
Publication of KR100331363B1 publication Critical patent/KR100331363B1/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyrane Compounds (AREA)

Abstract

본 발명은 사이클린 복합체의 하위단위체 성분들의 검출을 포함하는, 세포의 형질전환을 진단하기 위한 방법 및 진단 키트에 관한 것이다. 특히, 본 발명의 바업은 사이클린, PCNA, CDK들, 및 p21, p19 및 p16과 같은 저분자량 폴리펩티드들의 상호 작용에 관련된다. 본 발명은 또한 세포 증식의 억제제에도 관련된다.

Description

사이클린 복합체 재배열 및 그것과 관련된 용도(CVCLIN COMPLEX REARRANGEMENT AND USES RELATED THERETO)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (19)

  1. p21이 a)사이클린 키나아제, 사이클린, 또는 둘다와 복합체화되는 지, 또는 b)사이클린 키나아제, 사이클린, 또는 둘다와 복합체화되지 않는 지의 여부를 측정하는 것을 포함하며, p21이 사이클린 키나아제, 사이클린, 또는 둘다와 복합체화되어 있지 않다면, 세포의 형질전환의 표식이 되는 것을 특징으로 하는, 세포 형질전환의 진단 방법.
  2. 제1항에 있어서, p21이 사이클린 키나아제, 사이클린, 또는 둘다와 복합체화 되는 지의 여부를 측정하기 위하여 항체가 사용되는 것은 특징으로 하는 방법.
  3. 제1항에 있어서, 사이클린이 D-타입 사이클린 또는 A-타입 사이클린이고, 사이클린 키나아제가 CDK4인 것을 특징으로 하는 방법.
  4. p16이 a)사이클린 키나아제와 복합체화되는 지, 또는 b)사이클린 키나아제와 복합체화되지 않는 지의 여부를 측정하는 것을 포함하며, p16이 사이클린 키나아제와 복합체화되는 경우, 세포의 형질전환의 표식이 되는 것을 특징으로 하는, 세포 형질전환의 진단 방법.
  5. 제4항에 있어서, p16이 사이클린 키나아제와 복합체화되는 지의 여부를 측정하기 위하여 항체가 사용되는 것을 특징으로 하는 방법.
  6. 제4항에 있어서, 사이클린 키나아제가 CDK4인 것을 특징으로 하는 방법.
  7. p19가 a)사이클린과 복합체화되는 지, 또는 b)사이클린과 복합체화되지 않는 지의 여부를 측정하는 것을 포함하며, p19가 사이클린과 복합체화되면, 세포의 형질전환의 표식이 되는 것을 특징으로 하는, 세포의 형질전환의 진단 방법.
  8. 제7항에 있어서, p19가 사이클린과 복합체화되는 지의 여부를 측정하기 위하여 항체가 사용되는 것을 특징으로 하는 방법.
  9. 제7항에 있어서, 사이클린이 사이클린 A인 것을 특징으로 하는 방법.
  10. SEQ ID NO : 2의 아미노산 서열을 가지는 재조합 CDK5.
  11. CDK5를 코드화하는 cDNA.
  12. SEQ ID NO : 1의 누클레오티드 서열을 갖는 단리된 DNA.
  13. SEQ ID NO : 4의 아미노산 서열을 갖는 재조합 p16INK4.
  14. p16INK4를 코드화하는 cDNA.
  15. SEQ ID NO : 3의 누클레오티드 서열을 갖는 단리된 DNA.
  16. 환자로부터 단리된 세포의 샘플중에 p16단백질의 증가된 수준을 나타내는 세포의 수준을 측정하기 위한 p16INK4에 특이적인 항체를 포함하는, 형질전환된 세포를 확인하기 위한 진단 시험 키트.
  17. 제16항에 있어서, p16INK4에 특이적 항체가 SEQ ID NO : 4의 아미노산 서열을 갖는 단백질에 특이적인 것을 특징으로 하는 진단 키트.
  18. 환자로부터 단리된 세포의 샘플중에 p16 mRNA의 증가된 수준을 나타내는 세포의 수준을 측정하기 위한 p16INK4핵산 서열에 특이적인 핵산 프로브를 포함하는, 형질전환된 세포를 확인하기 위한 진단 세험 키트.
  19. 제18항에 있어서, 핵산 프로브가 SEQ ID NO : 3의 핵산 서열로부터 유도된 것을 특징으로 하는 진단 키트.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950701512A 1992-10-16 1993-10-18 사이클린복합체재배열및그것과관련된용도 KR100331363B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96330892A 1992-10-16 1992-10-16
US07/963308 1992-10-16
US99199792A 1992-12-17 1992-12-17
US07/991997 1992-12-17
PCT/US1993/009945 WO1994009135A1 (en) 1992-10-16 1993-10-18 Cyclin complex rearrangement and uses related thereto

Publications (2)

Publication Number Publication Date
KR950704483A true KR950704483A (ko) 1995-11-20
KR100331363B1 KR100331363B1 (ko) 2002-12-05

Family

ID=27130450

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950701512A KR100331363B1 (ko) 1992-10-16 1993-10-18 사이클린복합체재배열및그것과관련된용도

Country Status (11)

Country Link
EP (1) EP0665886B1 (ko)
JP (1) JP3485186B2 (ko)
KR (1) KR100331363B1 (ko)
AT (1) ATE242806T1 (ko)
AU (1) AU687764B2 (ko)
CA (1) CA2146965C (ko)
DE (1) DE69333043T2 (ko)
DK (1) DK0665886T3 (ko)
ES (1) ES2201064T3 (ko)
PT (1) PT665886E (ko)
WO (1) WO1994009135A1 (ko)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889169A (en) * 1991-05-16 1999-03-30 Cold Spring Harbor Laboratory Cell cycle regulatory protein p16 gene
US7550561B1 (en) 1991-05-16 2009-06-23 Cold Spring Harbor Laboratory p16INK4 polypeptides
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5596079A (en) * 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
US6211334B1 (en) * 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
US5962316A (en) 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6331390B1 (en) 1992-12-17 2001-12-18 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6043030A (en) * 1992-12-17 2000-03-28 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
AU692794B2 (en) * 1993-08-30 1998-06-18 Baylor College Of Medicine Senescent cell-derived inhibitors of DNA synthesis
US7691632B2 (en) 1993-11-18 2010-04-06 Cold Spring Harbor Laboratory Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression
CN1128049A (zh) * 1994-03-18 1996-07-31 犹他大学研究基金会 多肿瘤抑制因子基因种系突变及检测该基因癌肿倾向性的方法
US5989815A (en) * 1994-03-18 1999-11-23 University Of Utah Research Foundation Methods for detecting predisposition to cancer at the MTS gene
JPH08510651A (ja) * 1994-03-18 1996-11-12 ミリアド・ジェネティックス・インコーポレイテッド Ｍｔｓ遺伝子、それにおける変異、およびｍｔｓ遺伝子配列を用いる癌の診断方法
US6689561B1 (en) * 1994-04-14 2004-02-10 The Regents Of The University Of California Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
ES2233943T3 (es) * 1994-05-24 2005-06-16 Baylor College Of Medicine Mimeticos de inhibidores de la sintesis de dna derivados de celulas senescentes.
EP0775206A1 (en) * 1994-07-22 1997-05-28 Novartis AG Dual hybrid system
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
US5843756A (en) * 1995-06-07 1998-12-01 Myriad Genetics, Inc. Mouse MTSI gene
GB9509557D0 (en) 1995-05-11 1995-07-05 Univ Dundee PCNA binding substance
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
CA2227193A1 (en) 1995-07-17 1997-02-06 Xiaomei Jin P16 expression constructs and their application in cancer therapy
US5981702A (en) * 1995-09-21 1999-11-09 Cold Spring Harbor Laboratory Cyclin/CDK associated proteins, and uses related thereto
GB9519275D0 (en) * 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
DE69634044T2 (de) * 1995-10-05 2005-12-08 Sumitomo Electric Industries, Ltd. Menschliches Cyclin I und das dafür codierende Gen
US5672508A (en) * 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
ATE333465T1 (de) 1996-05-08 2006-08-15 Cyclacel Ltd Methoden und mittel zur hemmung der cdk4- aktivität
AU741632B2 (en) * 1998-02-18 2001-12-06 Theryte Limited Treating cancer
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
KR20000019888A (ko) * 1998-09-16 2000-04-15 성재갑 곤충세포를 이용한 cdk4/hc△p16 복합체의 제조방법 및이로부터 cdk4 단백질의 정제방법
KR20000038917A (ko) * 1998-12-10 2000-07-05 성재갑 곤충세포를 이용한 cdk6/p16 복합체의 제조방법
JP4842139B2 (ja) 2003-11-24 2011-12-21 カンジ，インコーポレイテッド 皮膚瘢痕の縮小
WO2006021803A2 (en) 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases

Also Published As

Publication number Publication date
DE69333043T2 (de) 2004-05-06
EP0665886A1 (en) 1995-08-09
WO1994009135A1 (en) 1994-04-28
EP0665886B1 (en) 2003-06-11
DK0665886T3 (da) 2003-10-06
JP3485186B2 (ja) 2004-01-13
PT665886E (pt) 2003-10-31
AU687764B2 (en) 1998-03-05
JPH08502649A (ja) 1996-03-26
DE69333043D1 (de) 2003-07-17
KR100331363B1 (ko) 2002-12-05
ES2201064T3 (es) 2004-03-16
CA2146965C (en) 2003-07-29
ATE242806T1 (de) 2003-06-15
CA2146965A1 (en) 1994-04-28
AU5444094A (en) 1994-05-09

Similar Documents

Publication Publication Date Title
KR950704483A (ko) 사이클린 복합체 재배열 및 그것과 관련된 용도(cyclin complex rearrangement and uses related thereto)
Bryan Vinblastine and microtubules: II. Characterization of two protein subunits from the isolated crystals
Bedford et al. Arginine methylation inhibits the binding of proline-rich ligands to Src homology 3, but not WW, domains
Laszlo et al. Actinomycin D: inhibition of respiration and glycolysis
Blackwell et al. Single-stranded-DNA binding alters human replication protein A structure and facilitates interaction with DNA-dependent protein kinase
Boehm et al. A growth factor‐dependent nuclear kinase phosphorylates p27Kip1 and regulates cell cycle progression
Abate et al. Redox regulation of fos and jun DNA-binding activity in vitro
Waisfisz et al. A physical complex of the Fanconi anemia proteins FANCG/XRCC9 and FANCA
Pfander et al. Dpb11 coordinates Mec1 kinase activation with cell cycle‐regulated Rad9 recruitment
Chen et al. Ubiquitin-associated (UBA) domains in Rad23 bind ubiquitin and promote inhibition of multi-ubiquitin chain assembly
Arvand et al. EWS/FLI1 up regulates mE2-C, a cyclin-selective ubiquitin conjugating enzyme involved in cyclin B destruction
Yotov et al. The alpha chain of the nascent polypeptide-associated complex functions as a transcriptional coactivator
Carvalho et al. Biological characterization of various forms of elongation factor 1 from rabbit reticulocytes
De La Cruz et al. Transient kinetic analysis of rhodamine phalloidin binding to actin filaments
Terai et al. Ras binding opens c‐Raf to expose the docking site for mitogen‐activated protein kinase kinase
Ku et al. Phosphorylation of human keratin 8 in vivo at conserved head domain serine 23 and at epidermal growth factor-stimulated tail domain serine 431
International Committee for Standardization in Haematology The measurement of total and unsaturated iron‐binding capacity in serum
Kim et al. Role of the 70-kDa subunit of human replication protein A (I): Single-stranded DNA binding activity, but not polymerase stimulatory activity, is required for DNA replication
Georg et al. BANK1 interacts with TRAF6 and MyD88 in innate immune signaling in B cells
US20080241852A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of endometriosis
Gercel-Taylor Diphenylamine assay of DNA fragmentation for chemosensitivity testing
Bagby et al. The button test: a small scale method using microdialysis cells for assessing protein solubility at concentrations suitable for NMR
Kae et al. Cyclic AMP signalling in Dictyostelium: G‐proteins activate separate Ras pathways using specific RasGEFs
Müller et al. Ultrasensitive and selective copper (ii) detection: Introducing a bioinspired and robust sensor
BRPI0708900A2 (pt) diagnàstico e prognàstico de estados màrbidos associados com dipeptidil peptidases

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
B701 Decision to grant
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee